Surveillance of invasive bacterial disease in Alaska, 2007
The Centers for Disease Control and Prevention's Arctic Investigations Program (AIP) in Anchorage, Alaska, maintains a statewide surveillance system for invasive diseases caused by Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and groups A and B streptococci. Laborat...
Other Authors: | |
---|---|
Language: | English |
Subjects: | |
Online Access: | http://stacks.cdc.gov/view/cdc/43836/ |
id |
ftcdc:oai:example.org:cdc:43836 |
---|---|
record_format |
openpolar |
spelling |
ftcdc:oai:example.org:cdc:43836 2023-05-15T15:08:22+02:00 Surveillance of invasive bacterial disease in Alaska, 2007 National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Division of Preparedness and Emerging Infections. Arctic Investigations Program. Alaska 32 numbered pages http://stacks.cdc.gov/view/cdc/43836/ eng eng cdc:43836 http://stacks.cdc.gov/view/cdc/43836/ Bacterial Infections Disease Notification Haemophilus Influenzae Neisseria Meningitidis Pneumococcal Infections Public Health Surveillance Streptococcal Infections ftcdc 2017-04-11T13:40:03Z The Centers for Disease Control and Prevention's Arctic Investigations Program (AIP) in Anchorage, Alaska, maintains a statewide surveillance system for invasive diseases caused by Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and groups A and B streptococci. Laboratories throughout the state are requested to send to AIP any isolates of these organisms recovered from a blood culture, CSF, or other normally sterile site in an Alaska resident. Isolate identification is confirmed and, when appropriate, serotyped and tested for antimicrobial susceptibility. The objectives of this system are to provide information on disease rates within the state, monitor the emergence of antimicrobial resistance, and to monitor the effectiveness of implemented vaccine programs, such as the 23-valent pneumococcal polysaccharide vaccine, the pneumococcal conjugate vaccine and Haemophilus influenzae type b vaccines. In 2007, the total numbers of cases of invasive disease caused by these organisms reported to AIP were 149 S. pneumoniae, 15 H. influenzae, 5 N. meningitidis, 32 group A Streptococci (GAS) and 38 group B Streptococci (GBS). Alaska Native people had higher rates of disease than non-Native people for all surveillance organisms. Rates of invasive pneumococcal disease were highest in the YK Delta. Summary -- Introduction -- Invasive Pneumococcal Disease -- Invasive Haemophilus influenzae -- Invasive Neisseria meningitidis -- Invasive Group A Streptococcus -- Invasive Group B Streptococcus -- References -- Appendix: MIC Interpretive Standards Definitions. Other/Unknown Material Arctic Alaska CDC Stacks (Centers for Disease Control and Prevention) Anchorage Arctic |
institution |
Open Polar |
collection |
CDC Stacks (Centers for Disease Control and Prevention) |
op_collection_id |
ftcdc |
language |
English |
topic |
Bacterial Infections Disease Notification Haemophilus Influenzae Neisseria Meningitidis Pneumococcal Infections Public Health Surveillance Streptococcal Infections |
spellingShingle |
Bacterial Infections Disease Notification Haemophilus Influenzae Neisseria Meningitidis Pneumococcal Infections Public Health Surveillance Streptococcal Infections Surveillance of invasive bacterial disease in Alaska, 2007 |
topic_facet |
Bacterial Infections Disease Notification Haemophilus Influenzae Neisseria Meningitidis Pneumococcal Infections Public Health Surveillance Streptococcal Infections |
description |
The Centers for Disease Control and Prevention's Arctic Investigations Program (AIP) in Anchorage, Alaska, maintains a statewide surveillance system for invasive diseases caused by Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and groups A and B streptococci. Laboratories throughout the state are requested to send to AIP any isolates of these organisms recovered from a blood culture, CSF, or other normally sterile site in an Alaska resident. Isolate identification is confirmed and, when appropriate, serotyped and tested for antimicrobial susceptibility. The objectives of this system are to provide information on disease rates within the state, monitor the emergence of antimicrobial resistance, and to monitor the effectiveness of implemented vaccine programs, such as the 23-valent pneumococcal polysaccharide vaccine, the pneumococcal conjugate vaccine and Haemophilus influenzae type b vaccines. In 2007, the total numbers of cases of invasive disease caused by these organisms reported to AIP were 149 S. pneumoniae, 15 H. influenzae, 5 N. meningitidis, 32 group A Streptococci (GAS) and 38 group B Streptococci (GBS). Alaska Native people had higher rates of disease than non-Native people for all surveillance organisms. Rates of invasive pneumococcal disease were highest in the YK Delta. Summary -- Introduction -- Invasive Pneumococcal Disease -- Invasive Haemophilus influenzae -- Invasive Neisseria meningitidis -- Invasive Group A Streptococcus -- Invasive Group B Streptococcus -- References -- Appendix: MIC Interpretive Standards Definitions. |
author2 |
National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Division of Preparedness and Emerging Infections. Arctic Investigations Program. |
title |
Surveillance of invasive bacterial disease in Alaska, 2007 |
title_short |
Surveillance of invasive bacterial disease in Alaska, 2007 |
title_full |
Surveillance of invasive bacterial disease in Alaska, 2007 |
title_fullStr |
Surveillance of invasive bacterial disease in Alaska, 2007 |
title_full_unstemmed |
Surveillance of invasive bacterial disease in Alaska, 2007 |
title_sort |
surveillance of invasive bacterial disease in alaska, 2007 |
url |
http://stacks.cdc.gov/view/cdc/43836/ |
op_coverage |
Alaska |
geographic |
Anchorage Arctic |
geographic_facet |
Anchorage Arctic |
genre |
Arctic Alaska |
genre_facet |
Arctic Alaska |
op_relation |
cdc:43836 http://stacks.cdc.gov/view/cdc/43836/ |
_version_ |
1766339748075405312 |